14.12.2012 • NewsDystarChinachemical industry

DyStar Is Transferring Textile Chemical Production to Nanjing

In order to strengthen its manufacturing capability for textile chemicals, DyStar plans to transfer the production from its plant in Hangzhou to the multi-purpose manufacturing site in Nanjing.

The plant in Nanjing started the production of dyes in 2006. Since then it has been expanded and almost 14.000 tons of textile dyes are now produced in Nanjing each year. The plan for next year is to increase production to about 20.000 tons.

This transfer will allow for increased scope in terms of chemical synthesis together with strict quality control in the extensive laboratory facilities.

During the last few years DyStar has been strongly focused on measuring and improving its environmental and social performance and for the last two years has published an annual sustainability report.

The production transfer is planned for the second half of 2013.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.